Susan Kuhnast
Leiden, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Variable cartilage degradation in mice with diet-induced metabolic dysfunction: food for thought.
Journal: Osteoarthritis and cartilage
Published: May 01, 2017
Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
Journal: Journal of lipid research
Published: January 21, 2015
Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising: A systematic review and meta-analysis of relevant preclinical studies and clinical trials.
Journal: European journal of pharmacology
Published: November 07, 2014
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
Journal: European heart journal
Published: August 22, 2014
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.
Journal: Journal of lipid research
Published: August 21, 2014
Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis.
Journal: Annals of the rheumatic diseases
Published: April 30, 2013
Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin.
Journal: Journal of hypertension
Published: December 03, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026